Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 22.20 is 22% below its 3-year average of 28.60, around the middle of its 3-year range (0.00–57.95).
As of the fiscal period ended Tuesday, June 30, 2026. 9.71% below its 12-month average of 24.59.
Reported quarterly quick ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 22.20.
QUICK RATIO (ACID-TEST)
22.20
QUICK RATIO (ACID-TEST) AVG TTM
24.59
QUICK RATIO (ACID-TEST) AVG 3Y
27.60
QUICK RATIO (ACID-TEST) AVG 5Y
N/A
QUICK RATIO (ACID-TEST) AVG 10Y
N/A
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
-9.71%
CURRENT VS 3Y AVG
-19.58%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
2.94
median of 513 covered companies
CURRENT VS SECTOR MEDIAN
+655.04%
vs the sector median at left
CG Oncology Inc.
Market Cap
$6.10B
Quick Ratio (Acid-Test)
22.20
TTM Avg
24.59
3Y Avg
27.60
5Y Avg
N/A
Market Cap
$6.20B
Quick Ratio (Acid-Test)
30.96
TTM Avg
15.27
3Y Avg
11.45
5Y Avg
10.17
Market Cap
$6.34B
Quick Ratio (Acid-Test)
3.82
TTM Avg
3.07
3Y Avg
3.52
5Y Avg
5.23
Market Cap
$5.84B
Quick Ratio (Acid-Test)
17.85
TTM Avg
17.70
3Y Avg
17.06
5Y Avg
17.77
Market Cap
$5.79B
Quick Ratio (Acid-Test)
3.49
TTM Avg
3.21
3Y Avg
3.75
5Y Avg
4.96
Market Cap
$6.52B
Quick Ratio (Acid-Test)
1.44
TTM Avg
1.17
3Y Avg
1.11
5Y Avg
1.26
Market Cap
$6.69B
Quick Ratio (Acid-Test)
0.87
TTM Avg
1.56
3Y Avg
2.48
5Y Avg
3.39
Market Cap
$6.71B
Quick Ratio (Acid-Test)
0.89
TTM Avg
1.19
3Y Avg
1.21
5Y Avg
1.11
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CG Oncology Inc. (CGON) | $6.10B | 22.20 | 24.59 | 27.60 | N/A |
| Ligand Pharmaceuticals Incorporated (LGND)vs › | $6.20B | 30.96 | 15.27 | 11.45 | 10.17 |
| Iovance Biotherapeutics, Inc. (IOVA)vs › | $6.34B | 3.82 | 3.07 | 3.52 | 5.23 |
| CRISPR Therapeutics AG (CRSP)vs › | $5.84B | 17.85 | 17.70 | 17.06 | 17.77 |
| Kiniksa Pharmaceuticals International, plc (KNSA)vs › | $5.79B | 3.49 | 3.21 | 3.75 | 4.96 |
| Amneal Pharmaceuticals, Inc. (AMRX)vs › | $6.52B | 1.44 | 1.17 | 1.11 | 1.26 |
| Hims & Hers Health, Inc. (HIMS)vs › | $6.69B | 0.87 | 1.56 | 2.48 | 3.39 |
| Chemed Corporation (CHE)vs › | $6.71B | 0.89 | 1.19 | 1.21 | 1.11 |
| Doximity, Inc. (DOCS)vs › | $5.42B | 6.08 | 6.53 | 6.56 | 6.07 |
| GRAIL Inc. (GRAL)vs › | $6.85B | 10.74 | 11.09 | 6.26 | 5.77 |
Quick Ratio
22.20
Excludes inventory
Current Ratio
22.22
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-06-30 | 22.20 |
| 2026-03-31 | 31.25 |
| 2025-12-31 | 24.58 |
| 2025-09-30 | 22.74 |
| 2025-06-30 | 22.15 |
| 2025-03-31 | 30.97 |
| 2024-12-31 | 35.30 |
| 2024-09-30 | 35.32 |
| 2024-06-30 | 47.57 |
| 2024-03-31 | 57.95 |
| 2023-12-31 | 13.62 |
| 2023-09-30 | 17.92 |
| 2023-06-30 | 57.95 |
| 2023-03-31 | 0.00 |
| 2022-12-31 | 9.54 |
